Position paper on the regulatory requirements for the authorisation of low- dose modified release ASA formulations in the secondary prevention of cardiovascular events.
Position paper on the regulatory requirements for the authorisation of low-dose modified release ASA formulations in the secondary prevention of cardiovascular events.